机构：[1]Department of Pathology, Dongguan Third People's Hospital, Dongguan, China[2]Department of Rheumatology and Immunology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China[3]Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China临床科室病理科中山大学肿瘤防治中心[4]Department of Oncology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Deregulation of serine/threonine kinase contributes to the development and progression of human diseases. PDZ-binding kinase (PBK) has been implicated in the malignant process of cancers, but its role and clinical significance in hepatocellular carcinoma (HCC) remains unclear. Here we show that PBK expression is increased and associated with larger tumor size, presence of vascular invasion, lymph node metastasis and poor overall and disease-free survivals in two independent cohorts of 879 patients with HCC. In vitro and in vivo data demonstrate PBK exerts oncogenic functions in HCC via activation of beta-Catenin signaling pathway. The inhibition of beta-Catenin by siRNAs or XAV-939 significantly attenuates PBK-mediated malignant phenotypes. PBK is further identified as a downstream effector of FoxM1. In clinical samples, PBK expression is positively correlated with the expression of FoxM1 and nuclear beta-Catenin. Collectively, these findings suggest PBK functions as an oncogene in HCC and the newly identified FoxM1/PBK/beta-Catenin axis serves as a promising prognostic factor as well as therapeutic intervention for HCC.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|2 区肿瘤学3 区细胞生物学
最新[2023]版：
无
第一作者：
第一作者机构：[1]Department of Pathology, Dongguan Third People's Hospital, Dongguan, China
共同第一作者：
通讯作者：
通讯机构：[3]Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China[4]Department of Oncology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
推荐引用方式(GB/T 7714)：
Yu-Feng Yang,Ying-Hua Pan,Yun Cao,et al.PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of beta-Catenin signaling in hepatocellular carcinoma[J].ONCOTARGET.2017,8(29):47195-47205.doi:10.18632/oncotarget.17587.
APA：
Yu-Feng Yang,Ying-Hua Pan,Yun Cao,Jia Fu,Xia Yang...&Qiu-Hong Tian.(2017).PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of beta-Catenin signaling in hepatocellular carcinoma.ONCOTARGET,8,(29)
MLA：
Yu-Feng Yang,et al."PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of beta-Catenin signaling in hepatocellular carcinoma".ONCOTARGET 8..29(2017):47195-47205
